2021年年度报告 公司代码：688189 公司简称：南新制药 湖南南新制药股份有限公司 2021 年年度报告 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2021, representing a year-on-year increase of 20%[14]. - The net profit for the period was 100 million CNY, with a profit margin of 20%[14]. - The company's operating revenue for the first half of 2021 was ¥431,197,318.05, a decrease of 25.73% compared to ¥580,561,386.78 in the same period last year[20]. - The net profit attributable to shareholders for the same period was ¥42,090,008.35, down 15.00% from ¥49,516,324.87 year-on-year[20]. - The company reported a revenue of 46,722.53 million yuan for the first half of 2021, a decrease of 19.52% compared to the same period last year[56]. - The net profit attributable to shareholders was 4,494.72 million yuan, down 9.23% year-on-year, while the net profit excluding non-recurring gains and losses decreased by 30.61% to 3,439.85 million yuan[56]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2021, representing a year-over-year growth of 20%[123]. - The company reported a total comprehensive income of CNY 52,809,517.70 for the first half of 2021, which includes a profit distribution of CNY -7,670,000.00[180]. Research and Development - Research and development expenses increased by 25%, totaling 50 million CNY, focusing on innovative drug formulations[14]. - The company invested 9.60% of its operating revenue in R&D, an increase of 1.64 percentage points compared to 7.96% in the same period last year[20]. - The company has a pipeline that includes 7 Class 1 new drug projects and 6 Class 3-4 generic drug projects, indicating a strong focus on innovation and market expansion[24]. - The company has established a comprehensive R&D platform, including research institutes and clinical centers, with core technical personnel having over ten years of experience in drug development[28]. - The company has developed three high-success-rate, practical, low-cost, and fast drug molecule design and discovery technologies, forming a core platform for lead compound design and discovery[36]. - The company is advancing several innovative drugs, including the anti-tumor drug Metafenib Tablets and the diabetes treatment drug Mefenamic Acid Tablets, which are in clinical research stages[34][35]. - The company has established a comprehensive new drug research and development system covering target analysis, molecular design, preclinical efficacy, and clinical research[54]. Market Expansion and Strategy - The company plans to launch two new products in Q3 2021, aiming to capture an additional 10% market share in the pharmaceutical sector[14]. - The company is expanding its market presence in Southeast Asia, targeting a revenue contribution of 15% from this region by the end of 2022[14]. - The company is actively pursuing market expansion by establishing multi-tiered marketing channels across 30 provinces in China[30]. - The company is focusing on the development of new products, including inhalation solutions and generics, to strengthen its market position in critical disease areas[35]. - The company is considering strategic acquisitions to bolster its product line, with a budget of $100 million allocated for potential deals[114]. - A strategic acquisition of a local biotech firm was completed, expected to enhance the company's product pipeline and increase revenue by 30 million CNY annually[14]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[14]. - The core product, Palivizumab, faces risks of competition and potential market share reduction due to possible successful imitation by other pharmaceutical companies[63]. - The company is exposed to risks related to the loss of core technical personnel and potential leakage of core technologies, which could adversely affect future profitability[62]. - The company must adapt to changes in national pharmaceutical policies, which could significantly impact its operational model and product pricing[66]. - The company is subject to industry risks due to intense competition in drug development, which may affect market demand for its products[64]. Shareholder and Financial Policies - The company plans to distribute cash dividends amounting to no less than 10% of the annual distributable profits after legal reserves and surplus reserves are deducted, provided there are no major investment plans or cash expenditures[100]. - The cumulative cash distribution over the next three years is expected to be at least 30% of the average annual distributable profits since the company went public[100]. - The company has outlined specific measures to ensure compliance with its commitments regarding share transfers and dividends[100]. - The company has committed to enhancing the management of raised funds to ensure their legal and reasonable use, with a focus on preventing risks associated with fund usage[116]. - The company has established a profit distribution policy to increase transparency and operability for shareholders[118]. Operational Efficiency - The company is implementing a new marketing strategy aimed at increasing brand awareness, with a budget allocation of 20 million CNY for digital marketing campaigns[14]. - The company has significantly improved production efficiency, product quality, management levels, and employee awareness, laying a solid foundation for sustainable development[59]. - The company has implemented new operational strategies that are projected to improve efficiency by 15%[113]. - The company aims to strengthen internal controls and improve operational efficiency to effectively manage business and operational risks[116]. Compliance and Governance - The company achieved a 100% pass rate in external inspections conducted by regulatory authorities in the first half of 2021, with no non-compliance feedback from 8 batches of external inspections[55]. - The company has not produced or developed any competing products with its subsidiaries as of the date of the commitment letter[102]. - The company will comply with new regulations regarding share circulation as they arise[93]. - The financial statements are prepared in accordance with the Chinese accounting standards, ensuring compliance and accuracy[191].

Financial Performance - The company's operating revenue for the third quarter was ¥154,484,830.03, a decrease of 42.48% compared to the same period last year[5] - The net profit attributable to shareholders was ¥8,794,648.91, down 59.20% year-on-year[5] - The basic earnings per share were ¥0.0628, reflecting a decline of 59.20% compared to the previous year[6] - The net profit excluding non-recurring gains and losses was ¥8,257,893.40, down 52.97% year-on-year[5] - Total operating revenue for the first three quarters of 2021 was CNY 621,710,154.59, a decrease of 26.8% compared to CNY 849,142,132.03 in the same period of 2020[19] - Net profit for the first three quarters of 2021 was CNY 53,104,254.92, a decline of 29.2% from CNY 74,769,473.79 in 2020[20] - Earnings per share for the first three quarters of 2021 was CNY 0.3839, compared to CNY 0.5538 in the same period of 2020[21] Research and Development - Research and development expenses totaled ¥17,673,886.49, a decrease of 46.03% from the same period last year, representing 11.44% of operating revenue[6] - The company is continuing to advance its major R&D projects, including inhalation solutions and dry suspensions, despite reduced R&D spending in the current period[10] - Research and development expenses for the first three quarters of 2021 were CNY 53,521,947.60, a decrease of 23.5% from CNY 69,933,608.52 in 2020[19] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥193,890,789.30, indicating significant cash outflow[6] - Operating cash inflow for the period was $449,822,839.79, a decrease from $665,525,044.40 in the previous period[24] - Net cash flow from operating activities was -$193,890,789.30, compared to -$176,913,789.24 in the prior period[24] - Cash inflow from investment activities totaled $1,832,299,959.54, significantly higher than $757,436.99 in the previous period[25] - The ending cash and cash equivalents balance was $320,141,775.85, compared to $1,053,207,485.20 at the end of the previous period[25] - Total assets increased to ¥2,343,515,269.37, marking a growth of 12.34% compared to the end of the previous year[6] - Total current assets as of September 30, 2021, amount to ¥1,972,906,560.02, an increase from ¥1,713,143,799.07 in the previous year[15] - Total assets as of September 30, 2021, are ¥2,343,515,269.37, compared to ¥2,086,018,842.19 at the end of 2020[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 7,310[12] - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., holds 40,000,000 shares, accounting for 28.57% of total shares[12] - The total number of shares held by the top 10 shareholders is 92,000,000, representing a significant concentration of ownership[12] Liabilities and Financial Position - Total liabilities as of the reporting date were CNY 711,999,937.86, an increase of 52.5% from CNY 466,867,765.60 in the previous year[19] - Short-term borrowings have significantly increased to ¥465,000,000.00 from ¥235,248,875.00, indicating a rise of 97.5%[15] - Total equity attributable to shareholders was CNY 1,608,819,430.90, slightly up from CNY 1,595,817,614.62 in the previous year[19] - Financial expenses increased to CNY 19,031,768.56 in 2021, compared to CNY 3,578,128.44 in the same period of 2020[19] Market and Operational Insights - The company attributed the decline in revenue and profit to ongoing impacts from the pandemic on marketing and logistics[10] - The company did not report any significant new product launches or market expansions during this period[26]

Financial Performance - Operating revenue decreased by 23.00% to CNY 250,724,188.68 year-on-year[8] - Net profit attributable to shareholders decreased by 6.45% to CNY 24,678,193.46 compared to the same period last year[8] - Basic and diluted earnings per share decreased by 6.42% to CNY 0.1763[8] - Total operating revenue for Q1 2021 was ¥250,724,188.68, a decrease of 23.0% compared to ¥325,616,521.18 in Q1 2020[24] - Net profit for Q1 2021 was ¥25,161,556.74, compared to ¥28,512,421.77 in Q1 2020, representing a decline of 11.6%[26] - The total comprehensive income for Q1 2021 was ¥25,161,556.74, compared to ¥28,512,421.77 in Q1 2020, indicating a decrease of 11.6%[26] Cash Flow - Net cash flow from operating activities was negative at CNY -68,941,958.20, a decrease of 1,036.69% compared to the previous year[8] - Cash flow from operating activities in Q1 2021 was ¥62,624,199.09, significantly lower than ¥336,025,280.86 in Q1 2020, a drop of 81.3%[29] - The net cash flow from operating activities for Q1 2021 was ¥48,455,203.26, a significant increase compared to ¥462,886.56 in Q1 2020, reflecting a strong operational performance[33] - The company reported a total cash outflow from operating activities of ¥131,566,157.29, compared to ¥328,665,125.50 in the previous year, indicating improved cash management[30] - The net increase in cash and cash equivalents for Q1 2021 was -¥66,966,727.69, contrasting with an increase of ¥1,047,648,886.56 in Q1 2020, indicating a challenging cash flow environment[33] Assets and Liabilities - Total assets increased by 8.75% to CNY 2,268,504,632.93 compared to the end of the previous year[8] - Current assets totaled CNY 1,907,509,863.58, compared to CNY 1,713,143,799.07, reflecting an increase of about 11.34%[19] - Total liabilities rose to CNY 624,191,999.60, up from CNY 466,867,765.60, marking a significant increase of approximately 33.6%[20] - The company's equity attributable to shareholders increased to CNY 1,620,495,808.08 from CNY 1,595,817,614.62, a growth of about 1.55%[20] - Non-current assets totaled CNY 360,994,769.35, down from CNY 372,875,043.12, indicating a decrease of about 3.2%[18] Research and Development - R&D expenditure as a percentage of operating revenue increased by 4.68 percentage points to 11.43%[8] - R&D expenses increased by 30.33% to ¥28,652,554.48, indicating a boost in R&D investment[13] - Research and development expenses increased to ¥28,652,554.48 in Q1 2021, up 30.3% from ¥21,984,332.59 in Q1 2020[25] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,262[11] - The largest shareholder, Hunan Xiangtou Holding Group Co., Ltd., holds 28.57% of the shares[11] Other Income and Expenses - Government subsidies recognized in the current period amounted to CNY 2,679,189.34[9] - The company reported a significant increase in other income by 1,547.30% to ¥2,679,189.34, mainly from government subsidies[13] - The company experienced a credit impairment loss of ¥-18,131,552.31 in Q1 2021, compared to ¥-2,840,994.02 in Q1 2020, reflecting a significant increase in losses[25] Investment Activities - Investment income was reported at ¥5,852,041.65, primarily from financial product returns[13] - The company reported an investment income of ¥5,852,041.65 in Q1 2021, with no comparable figure in Q1 2020[25] - Cash inflow from investment activities totaled ¥664,578,069.05, primarily driven by cash recovered from investments of ¥660,000,000.00[33] - The cash outflow for investment activities was ¥780,000,000.00, which included cash payments for investments of ¥660,000,000.00[33]

Financial Performance - The company's operating revenue for 2020 was CNY 1,029,142,035.73, representing a 1.47% increase compared to CNY 1,014,222,981.82 in 2019[21]. - Net profit attributable to shareholders for 2020 was CNY 127,972,024.63, a 39.90% increase from CNY 91,474,296.99 in 2019[21]. - The net cash flow from operating activities for 2020 was negative CNY 290,839,050.88, a significant decrease compared to a positive CNY 32,558,860.80 in 2019, reflecting a 993.27% decline[21]. - The company's total assets increased by 154.79% to CNY 2,086,018,842.19 at the end of 2020, up from CNY 818,717,329.92 at the end of 2019[21]. - The net assets attributable to shareholders rose by 379.85% to CNY 1,595,817,614.62 at the end of 2020, compared to CNY 332,563,289.99 at the end of 2019[21]. - Basic earnings per share for 2020 were CNY 0.9750, an increase of 11.92% from CNY 0.8712 in 2019[22]. - The weighted average return on net assets for 2020 was 10.25%, a decrease of 22.41% compared to 32.66% in 2019[22]. - The net profit after deducting non-recurring gains and losses for 2020 was CNY 120,169,831.42, a 36.30% increase from CNY 88,166,931.75 in 2019[21]. Research and Development - The company's R&D expenditure as a percentage of operating revenue increased to 10.50% in 2020, up from 7.08% in 2019, marking an increase of 3.42 percentage points[22]. - The total R&D investment for the year reached ¥108,038,020.55, a significant increase of 50.54% compared to the previous year[57]. - The company filed for 8 invention patents during the reporting period, with 2 granted, bringing the total granted patents to 16[58]. - The company has established a comprehensive new drug research and development system, enhancing its capability in drug discovery and development[75]. - The company is focusing on expanding its product pipeline with new formulations and delivery methods to address unmet medical needs[59]. - The company has multiple innovative drugs and specialty generic drugs in development for oncology, diabetes, and autoimmune diseases, including the anti-tumor drug Metafenib Tablets and the diabetes kidney disease drug Mefenamic Acid Tablets[45]. - The company has a pipeline of 8 new drug projects in the 1-2 category and 10 generic drug projects in the 3-4 category, indicating a strong focus on innovation[72]. Market and Sales Strategy - The company has established a comprehensive marketing network covering over 30 provinces in China[32]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[20]. - The company achieved a total revenue of approximately ¥1.03 billion for the year 2020, with a net profit attributable to shareholders of approximately ¥127.97 million[25]. - The company plans to continue expanding its sales efforts into lower-tier hospitals to drive future revenue growth, particularly for high-demand products like Palivizumab sodium injection[96][99]. - The company has implemented a new sales organization structure to penetrate lower-tier markets, aiming for sustained sales growth[81]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Tianzhi International Accounting Firm[5]. - The board of directors and supervisory board members have all attended the board meeting, ensuring accountability for the report's accuracy[5]. - The company has not disclosed any special arrangements for corporate governance[6]. - The company has described potential risks in the report, which investors should review in the section on risk factors[4]. - The company has not reported any instances where more than half of the directors could not guarantee the report's authenticity and completeness[7]. - The company has not violated decision-making procedures for providing guarantees[7]. Dividend Policy - The company plans to distribute a cash dividend of 2.91 RMB per 10 shares, totaling 40,740,000 RMB (including tax) based on a total share capital of 140,000,000 shares as of December 31, 2020, resulting in a cash dividend payout ratio of 31.84%[5]. - The company has committed to not producing or developing any competing products with Nanjing New Pharmaceutical Co., Ltd. and will not engage in any competitive business operations[177]. - The company will ensure compliance with the cash dividend distribution policy to meet shareholder expectations and maintain investor confidence[177]. Industry Trends - The pharmaceutical manufacturing industry in China saw a year-on-year increase of 5.9% in industrial added value above designated size[40]. - The pharmaceutical and biotechnology industry reported a revenue growth of 2.09% in the first three quarters of 2020, ranking 13th among 28 primary industries, with a net profit growth rate of 21.89%, ranking 5th[40]. - The number of domestic innovative drug approvals increased from 9 in 2018 to 16 in 2020, indicating a shift from generic to innovative drugs in the pharmaceutical industry[41]. - The sales revenue growth rate for biological products reached 13.7% in the first three quarters of 2020, making it the fastest-growing segment[42]. Risk Factors - The company faces risks related to the approval of new drug applications and potential market competition from generic versions of its key products[86][87]. - Future industry policies and regulations may significantly impact the company's operational model and product pricing strategies[88]. - The average price reduction for the fourth batch of national drug procurement was 52%, with the highest reduction reaching 96.82%, indicating a trend towards increased industry concentration and innovation pressure on companies[47].

重要内容提示： 关于召开 2022 年度暨 2023 年第一季度业绩说明会的公告 证券代码：688189 证券简称：南新制药 公告编号：2023-032 湖南南新制药股份有限公司 投资者可于 2023 年 5 月 25 日（星期四）至 5 月 31 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过湖南南新制药股份 有限公司（以下简称"公司"）邮箱 nanxin@nucien.com 进行提问。公司将在业 绩说明会上对投资者普遍关注的问题进行回答。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （三）会议召开方式：上证路演中心网络互动 三、参加人员 公司参加本次业绩说明会的人员包括：总经理张世喜先生，常务副总经理、 董事会秘书黄俊迪先生，副总经理、财务总监李亮先生（如有特殊情况，参会人 员可能进行调整）。 公司已于 2023 年 4 月 28 日在上海证券交易所网站（www.sse.com.cn）披露 了公司《2022 年年度报告》、《2022 年年度报告摘要》和《2023 年第一季度报告》。 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥303,227,799.34, representing a year-on-year increase of 54.09%[5] - The net profit attributable to shareholders was ¥12,532,756.73, reflecting a growth of 6.09% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 119.04% to ¥16,158,548.75[5] - Basic earnings per share increased by 5.97% to ¥0.0639[5] - Total operating revenue for Q1 2023 reached ¥303.23 million, a 54% increase from ¥196.78 million in Q1 2022[19] - Net profit for Q1 2023 was ¥14.36 million, compared to ¥6.98 million in Q1 2022, marking a 105.5% increase[20] - The company reported a total profit of ¥19.30 million for Q1 2023, up from ¥6.93 million in Q1 2022, representing a 178% increase[20] Research and Development - Research and development expenses totaled ¥34,015,766.79, marking a significant increase of 179.66%[6] - R&D expenses accounted for 11.22% of operating revenue, up by 5.04 percentage points year-on-year[6] - Research and development expenses surged to ¥34.02 million in Q1 2023, up from ¥12.16 million in Q1 2022, indicating a 179% increase[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,069,917,413.20, an increase of 5.94% from the previous year[6] - As of March 31, 2023, the total current assets amounted to RMB 1,631,204,722.21, an increase of 9.0% from RMB 1,496,172,292.33 on December 31, 2022[15] - The total liabilities increased to RMB 759,181,195.24, compared to RMB 657,420,475.62, representing a rise of 15.5%[16] - The total assets reached RMB 2,069,917,413.20, up from RMB 1,953,792,143.98, marking an increase of 5.9%[16] - The total equity attributable to shareholders increased slightly to RMB 1,326,897,296.06 from RMB 1,314,364,539.33, reflecting a growth of 0.2%[16] Cash Flow and Financial Health - Cash flow from operating activities generated a net amount of ¥2.67 million in Q1 2023, a significant recovery from a net outflow of ¥61.04 million in Q1 2022[23] - Cash and cash equivalents were reported at RMB 757,153,421.15, up from RMB 713,471,964.63, reflecting a growth of 6.1%[13] - Cash and cash equivalents at the end of Q1 2023 totaled ¥757.15 million, an increase from ¥674.86 million at the end of Q1 2022[24] Sales and Expenses - Total operating costs increased to ¥248.03 million in Q1 2023, up from ¥188.78 million in Q1 2022, representing a 31.5% rise[19] - Sales expenses rose to ¥181.42 million in Q1 2023, compared to ¥125.03 million in Q1 2022, which is a 45% increase[19] Credit and Inventory - The company incurred a credit impairment loss of ¥31.72 million in Q1 2023, compared to a loss of ¥5.71 million in Q1 2022, indicating a significant increase in credit risk[19] - Inventory levels rose to RMB 39,520,200.23 from RMB 27,014,850.74, showing a significant increase of 46.4%[15] Other Information - The company experienced a notable increase in sales of anti-influenza virus products due to a domestic flu outbreak, driving revenue growth[9] - The company reported a non-recurring loss of ¥3,625,792.02, primarily due to debt restructuring costs[9] - The company has not disclosed any new product developments or market expansion strategies in the current report[13]

2022年年度报告 公司代码：688189 公司简称：南新制药 湖南南新制药股份有限公司 2022 年年度报告 ...

Financial Performance - The company reported a total operating revenue of 400.40 million yuan, a decrease of 7.14% compared to the same period last year[4]. - The total profit for the period was 2.18 million yuan, down 95.43% year-on-year[4]. - The net profit attributable to shareholders was 17.81 million yuan, representing a decline of 57.68% compared to the previous year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 12.24 million yuan, a decrease of 61.21% year-on-year[4]. - The company's operating revenue for the first half of 2022 was approximately RMB 400.40 million, a decrease of 7.14% compared to RMB 431.20 million in the same period last year[24]. - The net profit attributable to shareholders for the first half of 2022 was approximately RMB 17.81 million, down 57.68% from RMB 42.09 million in the previous year[24]. - The basic earnings per share decreased to RMB 0.0909, a decline of 57.68% compared to RMB 0.2147 in the same period last year[23]. - The total profit for the same period was CNY 2.18 million, down 95.43% year-on-year[66]. - The net profit attributable to shareholders was CNY 17.81 million, a decline of 57.68% compared to the previous year[66]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 12.24 million, down 61.21% year-on-year[66]. Research and Development - The company's R&D investment accounted for 7.72% of operating revenue, down 2.68 percentage points from 10.4% in the previous year[23]. - The company has established a product lineup focusing on innovative drugs for major clinical needs, with 34 chemical drug varieties and 53 formulation production approvals, alongside 8 active pharmaceutical ingredient production approvals[31]. - The company is advancing its research pipeline with 8 Class 1 new drug projects, 2 Class 2 modified new drug projects, and 11 Class 3-4 generic drug projects currently under development[31]. - The total R&D investment decreased by 31.11% year-on-year to approximately ¥30.90 million, primarily due to the completion of major R&D work on several projects[49]. - The proportion of capitalized R&D investment increased by 7.00 percentage points to 20.38%, attributed to a decrease in expense-based R&D investment[50]. - The company has applied for 9 new invention patents and obtained 2 during the reporting period, bringing the total number of authorized patents to 32[48]. - The company’s core technologies include drug lead compound design and discovery, lead compound optimization, and chiral drug synthesis, which have not undergone significant changes during the reporting period[47]. - The company has 70 R&D personnel, representing 18.09% of the total workforce, an increase from 54 personnel and 17.65% in the same period last year[58]. Market Challenges - The company faced challenges due to the ongoing COVID-19 pandemic and the implementation of centralized drug procurement policies[4]. - The ongoing COVID-19 pandemic has significantly impacted the demand for the company's core product, "Liwai" (Paramiwe Sodium Chloride Injection), leading to a substantial decrease in sales revenue[63]. - The company is accelerating the development of new markets and enhancing its marketing network to mitigate the impact of the pandemic[64]. - The company faced risks related to the approval of new drugs, with existing products potentially facing market competition from generics[74]. - The ongoing COVID-19 pandemic negatively impacted the company's operations, leading to decreased demand and disruptions in production and sales[73]. Financial Position - The total assets at the end of the reporting period were approximately RMB 2.08 billion, a decrease of 2.24% from RMB 2.13 billion at the end of the previous year[24]. - The company's net assets attributable to shareholders increased by 1.28% to approximately RMB 1.41 billion from RMB 1.39 billion at the end of the previous year[24]. - The company reported a significant increase in interest income to CNY 9,730,127.49, up from CNY 6,073,036.17 in the previous year[191]. - The company reported a net loss of CNY 56,691,426.63, improving from a loss of CNY 74,503,191.29 in the previous period[184]. - Total liabilities decreased from CNY 736,886,724.25 to CNY 682,694,077.01, a reduction of approximately 7.35%[184]. - The total equity attributable to shareholders increased from CNY 1,393,196,824.37 to CNY 1,411,008,589.03, a growth of about 1.28%[184]. Environmental Compliance - The company has established an emergency response plan for environmental incidents in compliance with national regulations and has conducted regular drills[106]. - The company has installed online monitoring facilities for chemical oxygen demand, ammonia nitrogen, and total phosphorus, ensuring real-time pollution discharge monitoring[107]. - The company has complied with environmental protection laws and obtained necessary administrative permits for its projects[104]. - The company has received environmental impact assessment approvals for a project involving the production of 7 tons/year of Palivizumab and two other pharmaceutical raw materials[105]. - The company has not reported any measures taken to reduce carbon emissions during the reporting period[109]. Corporate Governance - The board of directors confirmed that all members attended the meeting and ensured the accuracy and completeness of the report[5]. - The report is unaudited, and the responsible persons have confirmed the financial report's authenticity and accuracy[5]. - The company has not disclosed any significant related party transactions with Nanjing New Pharmaceutical as of the date of the commitment[123]. - The company has committed to timely and full compensation for investor losses if any misleading statements lead to trading losses[132]. - The company will ensure compliance with legal issuance conditions to avoid significant impacts on investors[131].